Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506268 · ClinicalTrials.gov registry record · NA
COVID-19 SAFE Enrollment
A NA study of COVID-19, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 412
- Enrollment target
- 1
- Study location
NCT04506268: Completed NA study of COVID-19, sponsored by University of Pennsylvania.
NCT04506268 is a NA study of COVID-19 that has completed, run by University of Pennsylvania. The registered enrollment target is 412 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04506268, a NA study of COVID-19, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 412 participants
- Enrollment target
- 1
- Study location
Study Summary
In order to safely and effectively reopen businesses and universities across the US, institutions will need to develop approaches to rapidly identify COVID-19 cases and manage their spread while balancing program effectiveness, feasibility, costs, and scalability. The investigators will evaluate the implementation of a COVID-19 screening program that coordinates several existing systems at the University of Pennsylvania including saliva-based viral testing and test different outreach strategies (opt-in vs opt-out) to improve program enrollment.
Primary Outcome
The proportion of those invited that enroll in the study
Conditions Studied
Interventions
- BEHAVIORAL Opt-out Recruitment Email
- BEHAVIORAL Opt-in Recruitment Email
Study Locations (1)
Pennsylvania
- Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
What the finished NCT04506268 record still lists
NCT04506268 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Opt-out Recruitment Email is the first listed.
NCT04506268 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04506268 about?
NCT04506268 is a clinical study titled "COVID-19 SAFE Enrollment". In order to safely and effectively reopen businesses and universities across the US, institutions will need to develop approaches to rapidly identify COVID-19 cases and manage their spread while balancing program effectiveness, feasibility, costs, and scalability. The investigators will evaluate th...
What is the current status of trial NCT04506268?
This trial is currently completed. It is a NA study. The enrollment target is 412 participants. The study started on 2020-09-09. Estimated completion is 2020-10-30.
What conditions does trial NCT04506268 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04506268?
The interventions under investigation include: Opt-out Recruitment Email (BEHAVIORAL), Opt-in Recruitment Email (BEHAVIORAL).
Who is sponsoring clinical trial NCT04506268?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04506268 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04506268's enrollment target sits among peer trials
412 121st of 298 higher than 177 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI